Bruker shareholders approve acquisition of Bruker BioSpin

In addition to approving the acquisition of the Bruker BioSpin Group, stockholders also approved the name change of the company to Bruker Corporation. Tony Keller and Dirk Laukien, were elected to serve as directors of Bruker Corporation.

Frank Laukien, president and CEO of Bruker BioSciences, said: “We are very pleased to receive this clear vote and mandate from our non-affiliated shareholders to acquire Bruker BioSpin Group, which is now expected to close in February. The Bruker BioSpin Group is very complementary to Bruker BioSciences and the transaction should allow us to expand our combined market reach, leverage the Bruker brand, and enhance our ability to grow our profitability and cash flows.”